240 related articles for article (PubMed ID: 23006319)
1. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
[TBL] [Abstract][Full Text] [Related]
2. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of transformer 2β expression in prostate cancer.
Diao Y; Wu D; Dai Z; Kang H; Wang Z; Wang X
Int J Clin Exp Pathol; 2015; 8(6):6967-73. PubMed ID: 26261585
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
6. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
7. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
8. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
9. PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
Kao KR; Popadiuk P; Thoms J; Aoki S; Anwar S; Fitzgerald E; Andrews P; Voisey K; Gai L; Challa S; He Z; Gonzales-Aguirre P; Simmonds A; Popadiuk C
J Clin Pathol; 2018 May; 71(5):402-411. PubMed ID: 28924059
[TBL] [Abstract][Full Text] [Related]
10. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
11. Golgi phosphoprotein3 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis.
Jiang Y; Su Y; Zhao Y; Pan C; Chen L
Int J Clin Exp Pathol; 2015; 8(9):10615-24. PubMed ID: 26617771
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
Möller K; Wecker AL; Höflmayer D; Fraune C; Makrypidi-Fraune G; Hube-Magg C; Kluth M; Steurer S; Clauditz TS; Wilczak W; Simon R; Sauter G; Huland H; Heinzer H; Haese A; Schlomm T; Weidemann S; Luebke AM; Minner S; Bernreuther C; Bonk S; Marx A
Virchows Arch; 2020 Nov; 477(5):625-636. PubMed ID: 32417965
[TBL] [Abstract][Full Text] [Related]
13. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
14. GOLPH3 and YB-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
El-Maqsoud NMRA; Osman NAA; El-Hamid AMA; El-Bab TKF; Galal EM
World J Oncol; 2015 Dec; 6(6):473-484. PubMed ID: 28983350
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
[TBL] [Abstract][Full Text] [Related]
17. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
18. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.
Guo X; Xiong L; Zou L; Sun T; Zhang J; Li H; Peng R; Zhao J
Diagn Pathol; 2012 Aug; 7():96. PubMed ID: 22888955
[TBL] [Abstract][Full Text] [Related]
19. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
20. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
